KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Equity Average (2018 - 2026)

Amneal Pharmaceuticals has reported Equity Average over the past 8 years, most recently at -$90.4 million for Q4 2025.

  • For Q4 2025, Equity Average rose 10.98% year-over-year to -$90.4 million; the TTM value through Dec 2025 reached -$90.4 million, up 10.98%, while the annual FY2025 figure was -$90.4 million, 102.05% down from the prior year.
  • Equity Average for Q4 2025 was -$90.4 million at Amneal Pharmaceuticals, up from -$111.0 million in the prior quarter.
  • Over five years, Equity Average peaked at $387.2 million in Q1 2022 and troughed at -$122.3 million in Q2 2025.
  • A 5-year average of $119.2 million and a median of $147.6 million in 2023 define the central range for Equity Average.
  • On a YoY basis, Equity Average climbed as much as 10.98% in 2025 and fell as far as 453.7% in 2025.
  • Year by year, Equity Average stood at $375.1 million in 2021, then plummeted by 49.57% to $189.1 million in 2022, then tumbled by 53.94% to $87.1 million in 2023, then tumbled by 216.55% to -$101.5 million in 2024, then increased by 10.98% to -$90.4 million in 2025.
  • Business Quant data shows Equity Average for AMRX at -$90.4 million in Q4 2025, -$111.0 million in Q3 2025, and -$122.3 million in Q2 2025.